**Trotabresib**

Cat. No.: HY-137573  
CAS No.: 1706738-98-8  
Molecular Formula: $C_{21}H_{21}NO_4S$  
Molecular Weight: 383.46  
Target: Epigenetic Reader Domain  
Pathway: Epigenetics  
Storage:  
- Powder: -20°C 3 years, 4°C 2 years  
- In solvent: -80°C 6 months, -20°C 1 month

**SOLVENT & SOLUBILITY**

**In Vitro**  
DMSO: 50 mg/mL (130.39 mM; Need ultrasonic)

<table>
<thead>
<tr>
<th>Concentration</th>
<th>Mass (mL)</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mM</td>
<td>2.6078 mL</td>
<td>13.0392 mL</td>
<td>26.0783 mL</td>
<td></td>
</tr>
<tr>
<td>5 mM</td>
<td>0.5216 mL</td>
<td>2.6078 mL</td>
<td>5.2157 mL</td>
<td></td>
</tr>
<tr>
<td>10 mM</td>
<td>0.2608 mL</td>
<td>1.3039 mL</td>
<td>2.6078 mL</td>
<td></td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

**In Vivo**  
1. Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.08 mg/mL (5.42 mM); Clear solution

**BIOLOGICAL ACTIVITY**

**Description**  
CC-90010 (compound 1) is a reversible and orally active BET inhibitor. CC-90010 is applied in the study for advanced solid tumors\(^1\)\(^2\).

**REFERENCES**


[2]. V. Moreno, et al. CC-90010, a reversible, oral bromodomain and extra-terminal (BET) inhibitor in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory (R/R) non-Hodgkin lymphoma: Updated results of a phase I study.
Caution: Product has not been fully validated for medical applications. For research use only.
Tel: 609-228-6898  Fax: 609-228-5909  E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA